Bioxytran (BIXT) Cost of Revenue (2010 - 2018)
Bioxytran (BIXT) posted Cost of Revenue of $8115.0 for Q2 2018, down 46.78% sequentially from $15249.0 in Q1 2018, and down 58.16% YoY from $19396.0 in Q2 2017.
Bioxytran (BIXT) Cost of Revenue (2010 - 2018) Analysis & Trends
Bioxytran has reported Cost of Revenue for 9 years, with the latest figure at $8115.0 in Q2 2018.
- Quarterly Cost of Revenue fell 58.16% year-over-year to $8115.0 in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $94038.0 (changed 0.32% YoY) and the FY2017 annual result came in at $103979.0, up 7.97% from the prior year.
- Cost of Revenue eased to $8115.0 in Q2 2018 per BIXT's latest filing, from $15249.0 in the prior quarter.
- Over five years, Cost of Revenue peaked at $67792.0 in Q3 2015 and troughed at $8115.0 in Q2 2018.
- A 5-year average of $28578.1 and a median of $20932.5 in 2016 frame the typical range for Cost of Revenue.
- The sharpest annual moves came in 2014 and 2015: Cost of Revenue soared 421.99% in 2014, then plunged 73.16% in 2015.
- Over 5 years, Cost of Revenue stood at $65469.0 in 2014, then slumped by 57.3% to $27954.0 in 2015, then slipped by 19.62% to $22469.0 in 2016, then soared by 72.62% to $38785.0 in 2017, then plunged by 79.08% to $8115.0 in 2018.
- According to Business Quant data, Cost of Revenue over the past three periods registered $8115.0, $15249.0, and $38785.0 for Q2 2018, Q1 2018, and Q4 2017 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 298.26 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 387.98 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.21 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 8,115.00 |
| Jun 30, 2018 | 8,115.00 |
| Mar 31, 2018 | 15,249.00 |
| Mar 31, 2018 | 15,249.00 |
| Dec 31, 2017 | 38,785.00 |
| Dec 31, 2017 | 38,785.00 |
| Sep 30, 2017 | 31,889.00 |
| Sep 30, 2017 | 31,889.00 |
| Jun 30, 2017 | 19,396.00 |
| Jun 30, 2017 | 19,396.00 |
| Mar 31, 2017 | 13,673.00 |
| Mar 31, 2017 | 13,673.00 |
| Dec 31, 2016 | 22,469.00 |
| Dec 31, 2016 | 22,469.00 |
| Sep 30, 2016 | 38,200.00 |
| Sep 30, 2016 | 38,200.00 |
| Jun 30, 2016 | 18,829.00 |
| Jun 30, 2016 | 18,829.00 |
| Mar 31, 2016 | 16,806.00 |
| Mar 31, 2016 | 16,806.00 |